


PRODUCT INFORMATION



Erythromycin lactobionate

Item No. 17189

CAS Registry No.: 3847-29-8
Formal Name: 4-O-β-D-galactopyranosyl-D-gluconate erythromycin
MF: C₃₇H₆₇NO₁₃ • C₁₂H₂₂O₁₂
FW: 1,092.2
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Erythromycin lactobionate is supplied as a crystalline solid. A stock solution may be made by dissolving the erythromycin lactobionate in water. The solubility of erythromycin lactobionate in water is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Erythromycin lactobionate is a macrolide antibiotic and water-soluble form of erythromycin (Item No. 16486).¹ It is active against *S. aureus* and *S. pneumoniae*, as well as clinical isolates of group A streptococci (MICs = 0.6, 0.06, and 0.031 µg/ml, respectively).^{2,3} Erythromycin lactobionate (50 mg/kg) increases survival and reduces the number of lung colony forming units (CFUs) in a mouse model of *S. pneumoniae*-induced pneumonia.³ It also increases survival in mice infected with *P. aeruginosa* when administered at doses of 50 and 100 mg/kg.⁴ Formulations containing erythromycin lactobionate have been used in the treatment of various Gram-positive and Gram-negative bacterial infections.

References

1. Periti, P., Mazzei, T., Mini, E., *et al.* Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). *Clin. Pharmacokinet.* **16(4)**, 193-214 (1989).
2. Lebek, G. and Thöni, G. Effects *in vitro* of erythromycin, alone and in combination with penicillin, on staphylococci, pneumococci and streptococci. *Curr. Med. Res. Opin.* **5(2)**, 3-14 (1978).
3. Azoulay-Dupuis, E., Bedos, J.P., Vallée, E., *et al.* Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. *J. Infect. Dis.* **163(2)**, 319-324 (1991).
4. Hirakata, Y., Kaku, M., Tomono, K., *et al.* Efficacy of erythromycin lactobionate for treating *Pseudomonas aeruginosa* bacteremia in mice. *Antimicrob. Agents Chemother.* **36(6)**, 1198-1203 (1992).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/24/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM